HCW Biologics (HCWB) Stock Price, News & Analysis

Company Overview

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Key Stats

• Today's Range: $3.24 to $3.67
• 50-Day Range: $2.50 to $10.74
• 52-Week Range: $1.50 to $44.10
• Volume: 39,135 shs
• Average Volume: 73,907 shs
• Market Capitalization: $5.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

HCW Biologics Stock Analysis - MarketRank™

HCW Biologics scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

HCW Biologics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

HCW Biologics has a consensus price target of $30.00, representing about 817.4% upside from its current price of $3.27.

Amount of Analyst Coverage

HCW Biologics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of HCW Biologics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HCW Biologics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HCW Biologics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.06% of the float of HCW Biologics has been sold short.

Short Interest Ratio / Days to Cover

HCW Biologics has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HCW Biologics has recently decreased by 28.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HCW Biologics does not currently pay a dividend.

Dividend Growth

HCW Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

HCW Biologics has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for HCW Biologics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of HCW Biologics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $310,875.00 in company stock, which represents 5.9418% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, HCW Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $310,875.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

9.10% of the stock of HCW Biologics is held by insiders.

Percentage Held by Institutions

2.96% of the stock of HCW Biologics is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/10/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HCWB
• CIK: 1828673
• Web: www.hcwbiologics.com
• Phone: 954-842-2024
• Fax: 954-842-2037
• Employees: 40
• Year Founded: 2018

Price Target and Rating

• Average Price Target for HCW Biologics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +817.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($56.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.96 million
• Net Margins: -34.73%
• Pretax Margin: -29.73%
• Return on Equity: -486.87%
• Return on Assets: -29.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: $50 thousand
• Price / Sales: 104.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.06 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 1,600,000
• Free Float: 1,452,000
• Market Cap: $5.23 million
• Optionable: Not Optionable
• Beta: 2.32